PRELIMINARY PROGRAMME

25TH INTERNATIONAL SYMPOSIUM ON INFECTIONS IN THE CRITICALLY ILL PATIENT

25TH ANNIVERSARY

13th-14th February - BARCELONA 2020

ISICIP
**Description**

The aim of this two-day symposium is to review current concepts, technology and present advances in infections in critically ill patients.

Sepsis, Pulmonary Infections, Basic Research, Pulmonary Infections Treatment and Prophylaxis Therapy of severe infections will be the topics of the main sessions presented by experts who will review and update the new advances on infections in the critically ill patient. At the end of each session a Clinical Controversy, Pannel Discussion or Case Report Discussion will be organized.

**Organized by**

**Antonio Artigas, MD**
Corporación Sanitaria Universitaria Parc Taulí, CIBER Enfermedades Respiratorias, Autonomous University of Barcelona, Sabadell, Spain

**Jean Carlet, MD**
World Alliance Against Antibiotic Resistance (WAAAR), France

**Ricard Ferrer, MD**
Intensive Care Medicine Department, Vall d’Hebron University Hospital, Barcelona, Spain

**Michael Niederman, MD**
Division of Pulmonary and Critical Care Medicine, New York Presbyterian Hospital, Weill Cornell Medical College, USA

**Antoni Torres, MD**
Pulmonology Department, Clinic Hospital of Barcelona, CIBER Enfermedades Respiratorias, Barcelona, Spain

**Advisory Board**

<table>
<thead>
<tr>
<th>M. Antonelli, MD</th>
<th>Rome, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Bouza, MD</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>T. Calandra, MD</td>
<td>Lausanne, Switzerland</td>
</tr>
<tr>
<td>J. Chastre, MD</td>
<td>Paris, France</td>
</tr>
<tr>
<td>R. Ferrer, MD</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>J. Garnacho, MD</td>
<td>Seville, Spain</td>
</tr>
<tr>
<td>H. Gerlach, MD</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>J.L. Vincent, MD</td>
<td>Brussels, Belgium</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O. Hamzaoui, MD</th>
<th>Paris, France</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. Martin, MD</td>
<td>Marseille, France</td>
</tr>
<tr>
<td>I. Martin-Loeches, MD</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>M. Niederman, MD</td>
<td>New York, USA</td>
</tr>
<tr>
<td>S. Nseir, MD</td>
<td>Lille, France</td>
</tr>
<tr>
<td>J.A. Paiva, MD</td>
<td>Porto, Portugal</td>
</tr>
<tr>
<td>P. Pickkers, MD</td>
<td>Nijmegen, The Netherlands</td>
</tr>
<tr>
<td>C. Martin, MD</td>
<td>Marseille, France</td>
</tr>
<tr>
<td>J. Pugin, MD</td>
<td>Gèneve, Switzerland</td>
</tr>
<tr>
<td>M. Schultz, MD</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>J.L. Teboul, MD</td>
<td>Paris, France</td>
</tr>
<tr>
<td>A. Torres, MD</td>
<td>Barcelona, Spain</td>
</tr>
</tbody>
</table>

**List of Speakers**

<table>
<thead>
<tr>
<th>M. Antonelli, MD</th>
<th>Rome, Italy</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Artigas, MD</td>
<td>Sabadell, Spain</td>
</tr>
<tr>
<td>E. Bouza, MD</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>T. Calandra, MD</td>
<td>Lausanne, Switzerland</td>
</tr>
<tr>
<td>J. Carlet, MD</td>
<td>Paris, France</td>
</tr>
<tr>
<td>J. Chastre, MD</td>
<td>Paris, France</td>
</tr>
<tr>
<td>D. De Backer, MD</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>L. Fernández, MD</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>M. Ferrer, MD</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>R. Ferrer, MD</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>B. François, MD</td>
<td>Limoges, France</td>
</tr>
<tr>
<td>J. Garnacho, MD</td>
<td>Seville, Spain</td>
</tr>
<tr>
<td>H. Gerlach, MD</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>R. Guillamat, MD</td>
<td>Sabadell, Spain</td>
</tr>
</tbody>
</table>
Scientific Programme
Thursday, February 13th, 2020

08:00   Registration
08:45   Opening Session: 25th Anniversary
        A. Artigas, MD (Sabadell, Spain)
        J. Carlet, MD (Paris, France)
        R. Ferrer, MD (Barcelona, Spain)
        M. Niederman, MD (New York, USA)
        A. Torres, MD (Barcelona, Spain)

I. SEPSIS:

Moderators: A. Artigas, MD (Sabadell, Spain)
            H. Gerlach, MD (Berlin, Germany)

09:00   How 25 Years of Research Change my Practice in Sepsis?
        J.L. Vincent, MD (Brussels, Belgium)
09:20   Big data for Critical Infectious Diseases
        M. Antonelli, MD (Rome, Italy)
09:40   Are Sepsis Outcomes Predetermined?
        R. Ferrer, MD (Barcelona, Spain)
10:00   We Must Act Before the Hospital Admission
        H. Gerlach, MD (Berlin, Germany)
10:20   Discussion
10:30   Coffee-Break (Exhibition Area & Poster Discussion)

II. FLUID THERAPY AND VASOPRESSORS:

Moderators: J.L. Teboul, MD (Paris, France)
            D. De Backer, MD (Brussels, Belgium)

11:00   Current Use of Vasopressors in Septic Shock
        O. Hamzaoui, MD (Paris, France)
11:20   End-Points of Hemodynamic Resuscitation:
        What to Choose?
        TBC
11:40   Albumin Fluid Resuscitation In Patients With Septic Shock
        A. Artigas, MD (Sabadell, Spain)
12:00   When and How To Descalate Fluid and Vasopressor
        Therapy?
        C. Martin, MD (Marseille, France)
12:20   Non-Invasive Hemodynamic Monitoring Methods:
        Time to Replace Invasive Ones in Septic Shock?
        D. De Backer, MD (Brussels, Belgium)
12:20   Discussion
12:30   Debate: Early vs Delayed Norepinephrine Administration
        in Septic Shock?
        Moderator: A. Artigas, MD (Sabadell, Spain)
        Pro: J.L. Teboul, MD (Paris, France)
        Con: C. Martin, MD (Marseille, France)
13:10   Lunch
**III. PERSONALIZE SEPSIS CARE**

**Moderators:** R. Ferrer, MD (Barcelona, Spain)  
M. Schultz, MD (Amsterdam, The Netherlands)

14:30  
**Is Sepsis So Heterogeneous?**  
J.L. Vincent, MD (Brussels, Belgium)

14:50  
**Artificial Intelligence for Sepsis and Septic Shock: Still a Dream?**  
C. Martin, MD (Marseille, France)

15:10  
**Sepsis Phenotypes and Endotypes: The Way Forward?**  
T. Calandra, MD (Lausanne, Switzerland)

15:30  
**CRP and Albumin Kinetics in CA-BSI**  
P. Povoa, MD (Lisboa, Portugal)

16:10  
Discussion

16:20  
**Coffee-Break (Exhibition Area)**

---

**IV. NEW THERAPIES IN SEPSIS**

**Moderators:** T. Calandra, MD (Lausanne, Switzerland)  
R. Guillamat, MD (Sabadell, Spain)

16:50  
**Extracorporeal Pathogen and Endotoxin Elimination: Is The Horizon?**  
M. Antonelli, MD (Rome, Italy)

17:10  
**Aiming Immunomodulation Therapy at Sepsis**  
TBC

17:30  
**The Adrenomedulin Antibody**  
P. Pickkers, MD (Nijmegen, The Netherlands)

17:50  
**Cell Therapies in Sepsis: New Insights**  
TBC
Friday 14th February, 2020

08:30     How I Managed Pulmonary Infections 25 Years Ago and How I Am Doing Now?
          M. Niederman, MD (New York, USA)

V. SEVERE PULMONARY INFECTIONS

Moderators:  A. Torres, MD (Barcelona, Spain)
              J. Chastre, MD (Paris, France)

08:50     HAP In Non-Ventilated Patients
          M. Ferrer, MD (Barcelona, Spain)

09:10     Microbiota-Probiotics and Synbiotics
          M. Schultz, MD (Amsterdam, the Netherlands)

09:30     Phenotyping SCAP For Antibiotic and Non-Antibiotic
          Therapies and Prognosis
          A. Torres, MD (Barcelona, Spain)

09:50     Hyperoxemia as a Risk Factor for VAP
          S. Nseir, MD (Lille, France)

10:10     Role of Endotracheal Tube Biofilm in VAP
          L. Fernández, MD (Barcelona, Spain)

10:30     Aspiration Pneumonia
          M. Niederman, MD (New York, USA)

11:10     Discussion

11:20     Debate: Too Much of Good Thing:
          Early Antibiotic Therapy In Sepsis
          Moderator: I. Martin-Loeches, MD (Dublin, Ireland)
          Pro: R. Ferrer, MD (Barcelona, Spain)
          Con: T. Calandra, MD (Lausanne, Switzerland)

11:40     Coffee-Break (Exhibition Area & Poster Discussion)

VI. DIAGNOSTIC TOOLS IN PULMONARY INFECTION AND SEPSIS

Moderators:  M. Ferrer, MD (Barcelona, Spain)
              P. Povoa, MD (Lisboa, Portugal)

12:10     New Diagnostic Approaches for VAP
          J. Chastre, MD (Paris, France)

12:30     Progress in Early Pathogen Identification
          E. Bouza, MD (Madrid, Spain)

12:50     How Biomarkers Can Help in SCAP and Sepsis
          J. Pugin, MD (Genève, Switzerland)

13:10     Lunch
VII. OPTIMIZING ANTIMICROBIAL THERAPY and PREVENTION

**Moderators:** M. Niederman, MD (New York, USA)  
J. Carlet, MD (Paris, France)

14:10  Prevention of VAP: How We Made Progress?  
(The Antarctic Study)  
B. François, MD (Limoges, France)

14:30  Challenges To Antibiotic Stewardship  
J.F. Timsit, MD (Paris, France)

14:50  Consensus Statement On Antimicrobial De-Escalation  
In Critically Ill Patients  
J. Garnacho, MD (Sevilla, Spain)

15:10  Task Force On Practical Management of Invasive  
Candidiasis in Critically Ill Patients  
I. Martin-Loeches, MD (Dublin, Ireland)

15:30  Empirical Antifungal Therapy in the ICU:  
Time To Revisit  
T. Calandra, MD (Lausanne, Switzerland)

15:50  Optimal Treatment of Carbepenem Resistant  
Enterobacteriales Bacteriemia  
J.A. Paiva, MD (Porto, Portugal)

16:10  Ceftaroline in Severe CAP: Rationale in Real World Data  
A. Torres, MD (Barcelona, Spain)

16:30  Policy To Combat Antibiotic Resistance  
J. Carlet, MD (Paris, France)

16:50  **Closing Remarks**
**Dates:** February, 13th-14th, 2020

**Symposium Technical Secretariat**
Mccann
Ciutat de Granada 123
08018, Barcelona, SPAIN
Tel. +34 932 52 04 00
info.infections@mccann.es

**Conference Centre**
Paraninfo - Faculty of Medicine
Casanova Street, 143
08036 Barcelona (Spain)

**Registration Form**

<table>
<thead>
<tr>
<th>Registration</th>
<th>Prior to 31-12-2019</th>
<th>After 31-12-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members</td>
<td>□ 350 Euros</td>
<td>□ 400 Euros</td>
</tr>
<tr>
<td>Non members</td>
<td>□ 450 Euros</td>
<td>□ 500 Euros</td>
</tr>
<tr>
<td>Residents*</td>
<td>□ 200 Euros</td>
<td>□ 250 Euros</td>
</tr>
</tbody>
</table>

*A letter signed by the Institution responsible is required to get this fee.

The registration fees includes:
- Attendance to the Scientific Program and the Commercial Exhibition
- Conference Documents
- Certificate of Attendance
- Coffee Breaks

Under the data protection Act 15/99, we inform you that your personal data will be added to the McCann Erickson, SA database for promotional and other uses during the Congress. By filling in this application form, you authorize McCann Erickson, SA to use your personal data for the mentioned purposes. To exercise your right to access to, rectification and cancellation of this information, contact the Congress Secretariat.

**Registration**

<table>
<thead>
<tr>
<th>Registration</th>
<th>Prior to 31-12-2019</th>
<th>After 31-12-2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members</td>
<td>□ 350 Euros</td>
<td>□ 400 Euros</td>
</tr>
<tr>
<td>Non members</td>
<td>□ 450 Euros</td>
<td>□ 500 Euros</td>
</tr>
<tr>
<td>Residents*</td>
<td>□ 200 Euros</td>
<td>□ 250 Euros</td>
</tr>
</tbody>
</table>

*A letter signed by the Institution responsible is required to get this fee.

The registration fees includes:
- Attendance to the Scientific Program and the Commercial Exhibition
- Conference Documents
- Certificate of Attendance
- Coffee Breaks
Payment
TOTAL AMOUNT..............................

☐ I enclose cheque in Euros payable to McCann
   Cheque Nº.................................................................
   Bank...........................................................................
   Cheque amount.................................................Euros

☐ Credit card
   Card Nº
   Cardholder’s name.................................
   Expiry date
   Month                                   Year
   I authorize McCann to charge
   the amount of............Euros

Cancellation policy
Cancellations must be sent in written to the Technical Secretariat. Before January 7th an administration fee of 30 euros will be debited as management expenses. No fees will be refunded after this date. The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the Congress be hindered or prevented by unexpected, political or economic events or generally by force majeure, or should the nonappearance of speakers or others reasons necessitate programme changes. With reservation, the participant accepts this proviso.